-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
What Kind Of Shareholders Own Shanghai Bio-heart Biological Technology Co., Ltd. (HKG:2185)?
What Kind Of Shareholders Own Shanghai Bio-heart Biological Technology Co., Ltd. (HKG:2185)?
Every investor in Shanghai Bio-heart Biological Technology Co., Ltd. (HKG:2185) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. Companies that used to be publicly owned tend to have lower insider ownership.
Shanghai Bio-heart Biological Technology isn't enormous, but it's not particularly small either. It has a market capitalization of HK$17b, which means it would generally expect to see some institutions on the share registry. Our analysis of the ownership of the company, below, shows that institutions are noticeable on the share registry. Let's delve deeper into each type of owner, to discover more about Shanghai Bio-heart Biological Technology.
Check out our latest analysis for Shanghai Bio-heart Biological Technology
SEHK:2185 Ownership Breakdown July 7th 2022What Does The Institutional Ownership Tell Us About Shanghai Bio-heart Biological Technology?
Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.
As you can see, institutional investors have a fair amount of stake in Shanghai Bio-heart Biological Technology. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Shanghai Bio-heart Biological Technology's earnings history below. Of course, the future is what really matters.
SEHK:2185 Earnings and Revenue Growth July 7th 2022We note that hedge funds don't have a meaningful investment in Shanghai Bio-heart Biological Technology. The company's largest shareholder is Shanghai Baixinantong Enterprise Management Consulting L.P, with ownership of 11%. With 10% and 8.5% of the shares outstanding respectively, Shanghai Baihate Enterprise Management Consulting L.P. and TPG Capital, L.P. are the second and third largest shareholders.
We did some more digging and found that 10 of the top shareholders account for roughly 50% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat.
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage.
Insider Ownership Of Shanghai Bio-heart Biological Technology
The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
Our data suggests that insiders own under 1% of Shanghai Bio-heart Biological Technology Co., Ltd. in their own names. But they may have an indirect interest through a corporate structure that we haven't picked up on. Keep in mind that it's a big company, and the insiders own HK$1.9m worth of shares. The absolute value might be more important than the proportional share. Arguably, recent buying and selling is just as important to consider. You can click here to see if insiders have been buying or selling.
General Public Ownership
With a 50% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Shanghai Bio-heart Biological Technology. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.
Private Equity Ownership
With a stake of 8.5%, private equity firms could influence the Shanghai Bio-heart Biological Technology board. Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere.
Private Company Ownership
It seems that Private Companies own 20%, of the Shanghai Bio-heart Biological Technology stock. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.
Next Steps:
While it is well worth considering the different groups that own a company, there are other factors that are even more important. Case in point: We've spotted 2 warning signs for Shanghai Bio-heart Biological Technology you should be aware of, and 1 of them doesn't sit too well with us.
If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
百心安-B(HKG:2185)的每一位投資者都應該知道最強大的股東羣體。機構通常持有較成熟公司的股票,而內部人士擁有相當一部分較小公司的情況並不少見。過去屬於公眾所有的公司往往擁有較低的內部人持股比例。
百心安-B科技並不是很大,但也不是特別小。它的市值為170億港元,這意味着它通常預計會有一些機構出現在股票登記處。我們對公司所有權的分析如下所示,機構在股票登記處是顯而易見的。讓我們更深入地研究每種類型的所有者,以發現更多關於百心安-B科技的信息。
查看我們對百心安-B技術的最新分析
聯交所:2185擁有權分類2022年7月7日關於百心安-B科技,機構持股告訴了我們什麼?
機構通常在向自己的投資者報告時,以基準來衡量自己,因此一旦一隻股票被納入主要指數,它們往往會對這隻股票變得更加熱情。我們預計,大多數公司都會有一些機構登記在冊,特別是在它們正在增長的情況下。
如你所見,機構投資者在百心安-B科技持有相當多的股份。這意味着為這些機構工作的分析師已經看過了這隻股票,他們喜歡它。但就像其他人一樣,他們也可能錯了。如果多家機構同時改變對一隻股票的看法,你可能會看到股價迅速下跌。因此,下面百心安-B科技的盈利歷史值得一看。當然,未來才是真正重要的。
聯交所:2185盈利及收入增長2022年7月7日我們注意到,對衝基金沒有對百心安-B科技進行有意義的投資。公司最大股東為上海百新通企業管理諮詢有限公司,持股11%。上海拜哈特企業管理諮詢有限公司和TPG Capital,L.P.分別持有10%和8.5%的流通股,是第二大和第三大股東。
我們做了更多的挖掘,發現大股東中有10個約佔登記的50%,這意味着除了大股東之外,還有一些小股東,從而在一定程度上平衡了彼此的利益。
雖然研究一家公司的機構所有權數據是有意義的,但研究分析師的情緒以瞭解風向也是有意義的。分析師對該股的報道不多,但也不多。因此,它有獲得更多報道的空間。
百心安-B科技的內部人所有權
公司內部人的定義可能是主觀的,而且在不同的司法管轄區之間確實有所不同。我們的數據反映了個別內部人士,至少捕捉到了董事會成員。公司管理層管理企業,但首席執行官將向董事會負責,即使他或她是董事會成員。
我通常認為內部人持股是一件好事。然而,在某些情況下,這會讓其他股東更難讓董事會對決策負責。
我們的數據顯示,內部人士以自己的名義持有百心安-B不到1%的股份。但他們可能通過一種我們沒有注意到的公司結構擁有間接利益。請記住,這是一家大公司,內部人士持有價值190萬港元的股票。絕對值可能比比例份額更重要。可以説,最近的買入和賣出同樣重要。你可以點擊這裏,看看內部人士是在買入還是賣出。
一般公有制
持有50%股權的普通公眾,主要由個人投資者組成,對百心安-B科技有一定程度的影響力。這種規模的所有權雖然可觀,但如果決策與其他大股東不同步,可能不足以改變公司政策。
私募股權所有權
私募股權公司持有8.5%的股份,可能會對百心安-B創業板產生影響。有時我們會看到私募股權投資長期存在,但總的來説,它們的投資期限較短,而且--顧名思義--不會對上市公司進行太多投資。一段時間後,他們可能會考慮出售並將資本重新配置到其他地方。
私營公司所有權
看起來民營企業持有百心安-B 20%的股份。私營公司可能是關聯方。有時,內部人士通過持有一傢俬人公司來對上市公司感興趣,而不是以個人身份。雖然很難得出任何大致的中風結論,但值得注意的是,這是一個值得進一步研究的領域。
接下來的步驟:
雖然考慮擁有一家公司的不同集團是很值得的,但還有其他更重要的因素。一個恰當的例子:我們發現了百心安-B科技的2個警告信號你應該知道,他們中的一個和我們坐在一起不太好。
如果你像我一樣,你可能會想一想這家公司是會增長還是會萎縮。幸運的是,您可以查看這份顯示分析師對其未來預測的免費報告。
注:本文中的數字是使用過去12個月的數據計算的,指的是截至財務報表日期的最後一個月的12個月期間。這可能與全年的年度報告數字不一致。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧